Table 1.
Levels of Mast Cell Chemoattractants Decrease after Cetuximab Treatment
| Cytokine | WT | EGFR | EGFR + Cetuximab | Fold change: Cetuximab-treated nerve versus EGFR nerve (2−ΔΔCt method) |
|---|---|---|---|---|
| BDNF | Present | Present | Absent | n/a |
| MCP-1 | Absent | Present | Present | −4.14 (−4.35 to −3.94) |
| SCF | Present | Present | Present | −1.19 (−1.47 to −1.04) |
| TGF-β1 | Absent | Present | Present | −2.57 (−3.23 to −2.04) |
| VEGF | Present | Present | Present | −1.07 (−1.28 to +1.09) |
Mast cell chemoattractants BDNF, MCP-1, SCF, TGF-β1, and VEGF were measured by quantitative real-time PCR in WT or EGFR mice, or after exposure to Cetuximab (EGFR + Cetuximab) for 6 weeks starting at birth. Fold change was measured as described in Materials and Methods.